Strides Pharma Science Ltd
Ticker: STAR
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
934.70
Market Cap
8615.38
Debt/Equity
0.7267
ROE %
154.286
PB
3.3310
Promoter %
27.862
Pledge %
12.294
1Y Rev Growth %
99.023
5Y Rev Growth %
22.179
NP Margin %
45.366
NP Margin 5Y Avg %
6.389
Trading Reference
1M Return %
3.951
6M Return %
47.255
1Y Return %
37.287
% Away 52W High
4.675
% Away 52W Low
82.185
Daily Volume
9220861
Investment Verdict
Risky
Score 53/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Watch
Score 62/100 · Position size: 10%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Strides Pharma Science Ltd shows potential for growth amid market challenges.
✅ Positives
- Strong product pipeline in generics and specialty drugs
- Expanding global presence and partnerships
- Robust financial performance in recent quarters
⚠️ Negatives
- Regulatory challenges in key markets
- High competition in the pharmaceutical sector
- Dependence on a few major clients
Verdict
Moderate growth potential with some risks.
Recommendation: Consider buying on dips.
Upside Probability: 25% | Downside Probability: 15%
Last generated: 31/10/2025
More Options
R
Religare Enterprises Ltd
Religare Enterprises Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
SBI Nifty 50 ETF
The SBI Nifty 50 ETF is a decent investment option, reflecting the overall health of the Indian economy and its large-cap companies.
View details
B
BHARAT Bond ETF-April 2023-Growth
The BHARAT Bond ETF shows moderate potential but is hindered by several risks and valuation concerns.
View details
N
Network18 Media & Investments Ltd
Network18 Media & Investments Ltd faces significant challenges in growth and profitability, making it a risky investment at this time.
View details
G
GMR Power and Urban Infra Ltd
GMR Power and Urban Infra Ltd shows potential in a growing sector, but faces challenges in profitability and balance sheet strength.
View details
E
ELANTAS Beck India Ltd
ELANTAS Beck India Ltd shows decent fundamentals with consistent growth, but faces challenges in valuation and governance aspects.
View details
C
Campus Activewear Ltd
Campus Activewear Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
C
Cera Sanitaryware Ltd
Cera Sanitaryware Ltd shows decent potential for growth and profitability, but investors should be cautious of valuation and execution risks.
View details
K
Kalpataru Ltd
Kalpataru Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
G
Gujarat State Fertilizers & Chemicals Ltd
Gujarat State Fertilizers & Chemicals Ltd shows decent potential but faces several challenges that could impact future performance.
View details
S
Shilpa Medicare Ltd
Shilpa Medicare Ltd shows potential for growth, but faces challenges in profitability and execution risks.
View details
M
Manorama Industries Ltd
Manorama Industries Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
T
Thomas Cook (India) Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
R
Raymond Lifestyle Ltd
Raymond Lifestyle Ltd is facing several challenges that may hinder its growth potential, making it a risky investment at this time.
View details
P
P N Gadgil Jewellers Ltd
P N Gadgil Jewellers Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
K
Kirloskar Pneumatic Company Ltd
The company shows potential for growth but faces challenges in profitability and market competition.
View details
Business Overview
Strides Pharma Science Ltd is a leading Indian pharmaceutical company focused on developing and manufacturing high-quality generic and specialty medicines. Catering to global markets, Strides is committed to enhancing healthcare accessibility and affordability. With a strong emphasis on research and development, the company aims to deliver innovative solutions that meet diverse patient needs. Its robust pipeline and strategic partnerships position it as a key player in the pharmaceutical industry, making it a trusted choice for healthcare providers and patients alike.
- Leading Indian pharmaceutical company
- Focus on generic and specialty medicines
- Strong global market presence
- Commitment to affordable healthcare
- Robust R&D pipeline
- Strategic partnerships for growth
Investment Thesis
Strides Pharma Science Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company well for sustained growth and shareholder value creation.
- Strong promoter group with a proven track record in the pharmaceutical sector.
- Expanding digital services segment poised for substantial growth.
- Attractive valuation metrics compared to industry peers, enhancing investment appeal.
- Robust product pipeline and global market presence support future revenue growth.
- Commitment to innovation and quality strengthens competitive advantage.
Opportunity vs Risk
Opportunities
- Growing demand for generic drugs
- Expansion into international markets
- Strong pipeline of new products
- Strategic partnerships with healthcare firms
Risks ⚠️
- Regulatory challenges in multiple markets
- Intense competition in pharmaceuticals
- Currency fluctuations affecting profits
- Dependence on key customers
Peer Perspective
Strides Pharma Science Ltd trades at a discount to peers like Sun Pharma and Dr. Reddy's, reflecting concerns over margin stability; a consistent improvement in operational efficiency could catalyze a rerating.
Future Outlook
Strides Pharma Science Ltd is well-positioned for growth, driven by its robust pipeline and expanding market presence. Successful execution and effective cost control will be crucial to capitalize on emerging opportunities in the pharmaceutical sector.
AI FAQs for Retail Users
- Q: What does Strides Pharma Science Ltd do?A: Strides Pharma Science Ltd is a pharmaceutical company focused on developing and manufacturing generic drugs.
- Q: Is Strides Pharma listed on Indian stock exchanges?A: Yes, Strides Pharma is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in India.
- Q: What are the main markets for Strides Pharma?A: Strides Pharma operates primarily in the US, Europe, and emerging markets.
- Q: How does Strides Pharma ensure product quality?A: Strides Pharma follows stringent quality control measures and complies with international regulatory standards.
- Q: What factors can affect Strides Pharma's stock price?A: Factors include regulatory approvals, market demand, competition, and overall economic conditions.
📊 Stock Investment Checklist (100 Points)
Strides Pharma Science Ltd • Updated: 2025-09-18 01:10:25
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighModerate revenue growth with some fluctuations in profit.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent.
-
8ValuationHighP/E and P/B ratios are higher than industry average.
-
7BalanceHighManageable debt levels, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is stable, but some pledging exists.
-
5DriversGoodLimited catalysts identified; execution risks present.
-
5TechnicalsGoodWeak momentum and liquidity issues observed.
Final Score & Verdict
Score 68 / 100
• Decent
Strides Pharma Science Ltd shows potential but faces challenges in growth consistency and market competition.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100